Literature DB >> 15567554

Primary central nervous system lymphoma report of 32 cases and review of the literature.

Annie Dubuisson1, Bruno Kaschten, Jacques Lénelle, Didier Martin, Pierre Robe, Marie-France Fassotte, Isabelle Rutten, Manuel Deprez, Achille Stevenaert.   

Abstract

We retrospectively analyzed 32 cases of primary central nervous system lymphoma (PCNSL). Five cases were diagnosed in the period 1987-1994, for 27 cases in the period 1995-2002. There were 17 men and 15 women whose median age was 69 years. Three patients were immunodeficient. The commonest symptoms were focal deficit (16 patients) and cognitive/behaviour disturbances (14 patients). Radiologically, a total of 47 contrast-enhancing lesions were observed in 32 patients; 18 patients had deep-seated lesions. All but two patients underwent histological diagnosis following craniotomy (11 patients) and/or stereotaxic biopsy (22 patients); diagnosis was obtained on CSF cytology in one patient with a third ventricle tumour. In the last patient, the diagnosis was based on the finding of marked tumour shrinkage under corticotherapy, despite two negative histological examinations. Treatment included surgical resection (10 patients), chemotherapy (25 patients) and/or radiotherapy (12 patients). According to the therapeutic recommendations of the GELA (Groupe d'Etude des Lymphomes de l'Adulte), 19 patients received at least two courses of high-dose methotrexate; intrathecal chemotherapy was used in 20 patients with methotrexate and/or cytosine arabinoside. Radiation therapy consisted of whole brain irradiation followed by a boost on tumour site. Nine patients received a combined treatment of chemotherapy and radiotherapy. Twelve patients showed rapid progression to death. At the time of last contact, 28/32 patients (88%) had died, all from PCNSL disease or from complications due to its treatment. The median survival time was 13.9 months. We conclude that PCNSL is an increasingly frequent tumour. The diagnosis is obtained by stereotactic biopsy in the majority of cases. The prognosis appears dismal despite an intensive multidisciplinary therapeutic approach.

Entities:  

Mesh:

Year:  2004        PMID: 15567554     DOI: 10.1016/j.clineuro.2004.03.005

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  MRI findings of primary CNS lymphoma in 26 immunocompetent patients.

Authors:  Dong Zhang; Liang-Bo Hu; Tobias D Henning; Elisabeth M Ravarani; Li-Guang Zou; Xiao-Yuan Feng; Wen-Xian Wang; Li Wen
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

2.  A Rare Presentation of Primary Central Nervous System Lymphoma in an Immunocompetent Patient.

Authors:  Nathan DeRon; Maheen Ahmed; Dylan Lopez; Ahmed Alobaidi
Journal:  Cureus       Date:  2022-04-05

3.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

4.  Primary central nervous system lymphoma presenting as a pure third ventricular lesion: a case report.

Authors:  Mehdi Sasani; Muzaffer Bayhan; Hadi Sasani; Tuncay Kaner; Tunc Oktenoglu; Gokhan Cakiroglu; Ali Fahir Ozer
Journal:  J Med Case Rep       Date:  2011-05-28

5.  Primary central nervous system lymphoma with preceding spontaneous pseudotumoral demyelination in an immunocompetent adult patient: A case report and literature review.

Authors:  Junkoh Yamamoto; Shohei Shimajiri; Yoshiteru Nakano; Shigeru Nishizawa
Journal:  Oncol Lett       Date:  2014-04-04       Impact factor: 2.967

6.  Delayed Contrast Enhancement in Magnetic Resonance Imaging and Vascular Morphology of Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): A Retrospective Study.

Authors:  Dandan Liu; Xiaojun Liu; Zhaogui Ba; Limei Xie; Jiwu Han; Dexin Yu; Xiangxing Ma
Journal:  Med Sci Monit       Date:  2019-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.